Skip to content
Careers
Contact Us
About DBV
Overview
Leadership
Our Pipeline
Overview
Clinical Trials
VIASKIN
®
peanut patch
VIASKIN
®
milk patch
VIASKIN
®
milk patch for EoE
Expanded Access Program
Our Science
Overview
VIASKIN
®
patch technology
Scientific Publications & Presentations
Investors
Investor Overview
News
Financial Information
SEC Filings
AMF Regulated Information
Events
Annual General Meetings
Stock Information
Corporate Governance
FAQs
Newsroom
Press Releases
Media Kit
AGM 2021 – US Proxy Statement
By
Jonathan
/
April 28, 2021
←
Previous AGM Doc
Next AGM Doc
→
About DBV
Overview
Leadership
Our Pipeline
Overview
Clinical Trials
VIASKIN
®
peanut patch
VIASKIN
®
milk patch
VIASKIN
®
milk patch for EoE
Expanded Access Program
Our Science
Overview
VIASKIN
®
patch technology
Scientific Publications & Presentations
Investors
Investor Overview
News
Financial Information
SEC Filings
AMF Regulated Information
Events
Annual General Meetings
Stock Information
Corporate Governance
FAQs
News
Careers
Contact Us
English
Français
About DBV
Overview
Leadership
Our Pipeline
Overview
Clinical Trials
VIASKIN
®
peanut patch
VIASKIN
®
milk patch
VIASKIN
®
milk patch for EoE
Expanded Access Program
Our Science
Overview
VIASKIN
®
patch technology
Scientific Publications & Presentations
Investors
Investor Overview
News
Financial Information
SEC Filings
AMF Regulated Information
Events
Annual General Meetings
Stock Information
Corporate Governance
FAQs
News
Careers
Contact Us
English
Français
Scroll to Top